The present invention discloses a process for making Clopidogrel Bisulfate Form I which comprises dissolving Clopidogrel Bisulfate Form II in a solublizing solvent at room tempreature to form a solution; adding an anti-solvent to the said solution till turbid; stirring the said turbid solution; collecting the precip...

The present invention relates to novel processes for preparation of Canagliflozin. The present invention further relates to novel compounds, which are used in the synthesis of Canagliflozin. The present invention further relates to processes for preparation of Canagliflozin using these novel compounds. ...

The present invention relates to a purification process using acetonitrile as a solvent to yield pure camphor sulfonate salt of (S)-(+)-methyl-α-5-[4,5,6,7-tetrahydro[3,2-c]thienopyridyl]-(2-chlorophenyl)acetate, an intermediate for the preparation of highly pure (S)-(+)-clopidogrel bisulfate.

One aspect of the invention resides in a monolithic sustained release composition of glipizide for patients with non-insulin dependent diabetes mellitus that exhibits a breakdown after ingestion by a patient in conformity with a zero-order kineetic. the present invention provides a composition of a glipizide and a h...

N/A

yes

The present invention discloses a process for preparation of highly pure Adapalene, chemically designated as 6-[3-(1-adamantyl)-4-methoxy phenyl]-2-naphthoic acid (I) comprising: a) reacting 1-adamantanol with 4-bromophenol (ІІ) in presence of sulphonic acid with or without the use of organic solvent to give 2-(1-...

The present invention relates to an improved process for preparation of (R)-2-acetamido-N-benzyl-3-methoxypropionamide, also known as Lacosamide. The present invention also relates to a process for preparation of (R)-N-benzyl-2-amino-3-hydroxy propionamide or salts thereof, an intermediate used in the synthesis of L...

The present invention relates to a process for preparation of Dabigatran etexilate or pharmaceutically acceptable salt thereof. The present invention relates to novel compounds, in particular Ethyl-3-{[(2-formyl-]-methy]-lH-ben2imidazole-5-yl) carbonyl] -(2-pyridinyl) amino} propanoate and Ethyl-3-{[(2-dichloromethy...

The present invention relates to a process for preparation of Bazedoxifene or pharmaceutically acceptable salt thereof. The present invention further relates to a novel polymorphic form of 5-Benzyloxy-2-{4-benzyloxy-phenyl)-3-memyl-1-[4-(2-hexamethyleneimine-l-yl-ethoxy)-benzyl]-lH-indole, a key intermediate used in...

The present invention relates to an improved process for the preparation of Chlorothiazide and pharmaceutically acceptable salts thereof. The present invention relates to novel polymorphs of Chlorothiazide and Chlorothiazide salts, in particular Chlorothiazide sodium. The present invention further relates to pharmac...

Disclosed herein are pharmaceutical compositions comprising (a) Irbesartan or pharmaceutically acceptable salt thereof and (b) optionally a diuretic; and wherein said composition comprises less than about 70% by weight of Irbesartan or a pharmaceutically acceptable salt thereof and are free of surfactants. ...

The present invention relates to a process for the preparation of Palonosetron or pharmaceutically acceptable salt thereof, in particular Palonosetron hydrochloride.

Disclosed herein is an improved process for preparation of Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4mmol/g. Further, the invention discloses Sevelamer hydrochloride compositions and a novel process for preparation of said compositions comprising high shear non-aqueous granulation. ...

The present invention relates to an improved process for the preparation of 3-(N-me!hy]-2(R)- pyrrolidinyl methyl)-5-[2-(phenyl sulfonyl) ethyl]-]1H-indole or pharmaceutically acceptable salts thereof, particularly 3-(N-methyl-2(R)-pyrrolidinyl methyl)-5-[2-(phenyl sulfonyl) ethyl]-lH-indole hydrobromide (Eletriptan...

The present invention relates to a novel process for preparation of Pregabalin. The present invention further relates to compounds represented by Formula II, III, III A, IV and V and process for preparation thereof. The present invention further relates to the use of these compounds in the preparation of Pregabalin....

The present invention relates to an improved process for preparation of Sitagliptin or pharmaceutically acceptable salts thereof. The present invention further relates to novel polymorphs of Sitagliptin salts and process for preparation thereof.

A process for the production of pramlintide of Formula 1: H-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala'-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val- His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn- Thr-Tyr-NH2 comprising: a) coupling Fmoc-Tyr(X)-OH to acid labile solid support with substitution value ra...

The present invention relates to analytical methods such as molecular weight determination of polypeptide in particular Glatiramer acetate. The present invention further relates to an improved process for preparation of polypeptides or pharmaceutically acceptable salts thereof particularly Glatiramer acetate also kn...

The present invention relates to a process for preparation of Metformin embonate/pamoate Form I or Form II, substantially free of other polymorphic forms. The present invention further relates to novel polymorphic forms of Metformin pamoate/ embonate and processes for preparation thereof.

The present invention relates to an improved process for the large scale synthesis of cyclic heptapeptide using Fmoc solid phase synthesis technique. The described process assembles the peptide on a solid support resin by coupling to one another by peptide bonds to obtain a peptide wherein the coupling of cysteine...

The present invention provides an improved process for preparation of highly pure Zolmitriptan or (S)-4-[[3-(2-(dimethylamino)ethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one.

The present invention relates to an improved process for the preparation of 3-(N-methyl-2(R)-pyrrolidinylmethyl) -5-[2-(phenyJsulfonyl)ethyl]- lH-iiidole hydrobromide (Eletriptan hydrobromide), in particular Eletriptan hydrobromide monohydrate. The present invention further relates to an improved process for prepara...

Disclosed herein the process for the preparation of  l-(4-chlorophenyl)-5-isopropyl-biguanide hydrochloride (Proguanil hydrochloride), Formula-I, an antimalarial agent.

The present invention discloses a novel process and novel intermediates for the preparation of 4-[2-(di-n-propyl amino)ethyl]-1,3-dihydro-2H-indol-2-one,commonly known as Ropinirole (I),being useful in cardiovascular therapy and an agent useful in treating Parkinson"s disease.

Stable oral antidiabetic formulation of glipizide and metformin hydrochloride comprising inclusion complex of glipizide with cyclodextrin and non-ionic surfactant.Also process for the preparation of the formulation which comprises dry mixing metformin hydrochloride and inclusion complex of glipizide with cyclodextri...

N/A

process for the preparation of highly pure (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide (Entacapone). It comprises condensing3,4-dihydroxy-5-nitro benzaldehyde with N,N-diethyl cyano acetamide in an organic solvent in the presence of an organic base and an acid under reflux conditions followed...

The present invention discloses a novel oxalate salt of 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl]5 methyl piperidine commonly known as Donepezil (I); its polymorphic forms and method of preparation thereof.

N/A

The present disclosure provides an affinity polypeptide for the purification of a recombinant biologically active protein or polypeptide. Further, the present disclosure provides a fusion recombinant protein or polypeptide wherein the fusion recombinant protein comprises of at least two components, a biologically ac...

The present invention discloses a process for the synthesis of N-[4-Cyano-3-(trifluoromethyl) phenyl]-3-[(4-fluorophenyl) sulphonyl]-2-hydroxy-2-methyl propanamide (F0rm I). The invention discloses a novel reagent for oxidation of N-[4-Cyano-3-(trifluoromethyl) phelyl]- 3-[(4-fluorophenyl) thio]-2hydroxy-2methyl pro...

The present invention relates to an improved process for the preparation of 11-(Z)-[3-(Dimethylamino) propylidene]-6, 11-dihydrodibenz[b,e]oxepin-2-acetic acid (Olopatadine hydrochloride) by reaction of 11-oxo-6,11-dihydrodibenz[b,e] oxepin-2-acetic acid with Grignard reagent of 1-halo-3-dimethylaminopropane and fur...

The present invention discloses a novel process for purification of trans-4-methy1 cyclohexylamine HCL and 4-[2-(3-Ethyl-4-methyl-2-carbonl pyrrolidine amido) ethyl] benzene sulfonamide used in the synthesis of 3-Ethyl-2, 5-dihydro-4-methyl-N- [2-[4-[[[[(trans-4-methyl cyclohexyl) amino] carbony1] amino] sulfony1] p...

The present invention provides novel process for preparation of Sevelamer carbonate used as an antihyperphophatemic agent.

The present invention relates to an improved process for the preparation of N6 –(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L- α-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1→ 6)-disulfide of formula (1). Which involves assembling amino acid residues and a thioalkyl carboxylic acid with appropriate prot...

Sevelamer carbonate is prepared from Sevelamer hydrochloride which comprises the steps of; a) treating Sevelamer hydrochloride with base to obtain Sevelamer base and b) combining obtained Sevelamer base with suitable carbonate source to get Sevelamer carbonate.

he present invention relates to cloning and expression of a novel nucleic acid equence encoding Enterokinase, wherein the expression has been carried out in le protease positive background. The present invention further provides an improved process for production of Enterokinase. The method disclosed in the ivention...

The present invention relates to an improved process for the preparation of 2-[2-(4-Dibenzo[b,f][1,4] thiazepin-11-yl-1-piperazinyl)ethoxy] ethanol hemifumarate (Quetiapine hemifumarate).

The invention discloses a novel nesiritide synthetic cDNA chimera encoding human b-type natriuretic peptide (hBNP) or nesiritide and a process for the preparation of the said novel chimera. Further the invention discloses the use of nesiritide synthetic cDNA chimera to obtain an expressible construct to produce matu...

Disclosed herein are stable pharmaceutical compositions of Acarbose alone or in combination with other antidiabetic agents and a process for preparation of compositions.

The present invention relates to process for preparing micronized Valsartan with particle size distribution of d10 less then 5µ, d50 less than 10 µ and d90 less then 20 µ preferably d90 < 10 µ.

The present invention relates to an improved process for the preparation of N,N- dimethyl-5-(l H-1,2,4-triazol-1 -ylmethyl)-1 H-Indole-3-Cthanamine monobenzoate (Rizatriptan benzoate). The present invention further relates to an isolated impurity of Rizatriptan, Rizatriptan methyl chloride, its preparation and its...

The present invention relates to process for preparation of dextrorotatory isomer of 6-(5-chloro-pyrid-2-yl)-5-[(4-methyl -1-piperazinyl) carbonyloxy] -7-oxo-6,7-dihydro-5H-pyrrolo [3,4-b] pyrazine (Eszopiclone), Formula ( I ), a hypnotic agent. The invention further relates to recovery of key starting material (IV)...

The present invention discloses a process for the preparation of rhPTH (1-34) also known as teriparatide by construction of a novel nucleotide, as an Ncol IXhoI fragment as set forth in SEQ.ID No.:l encoding a chimeric fusion protein as set forth in SEQ.ID No.:2 comprising of a fusion partner consisting of 41 amino ...

The present invention relates to process for preparation of (S)-N-[2-(l,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl] propionamide (Ramelteon) of in pure isomeric form and free from unwanted impurities. The present invention further relates to novel intermediates used for the preparation of Ramelteon and proces...

The invention relates to a stable pharmaceutical compositions and a process for the preparation of the same, which is used for the prevention and treatment of osteoporosis and osteoarthritis comprising a combination of a therapeutically effective amount of Calcitriol; a therapeutically effective amount of elemental ...

The present invention relates to an improved process for the preparation and purification of Prostaglandins and analogues thereof.

The present invention discloses a rapid resolution process of racemic clopidogrel base followed by conversion of the resolved (S) isomer to crystalline Clopidogrel bisulfate Form I. The invention also discloses novel racemization process of the unwanted (R) isomer of clopidogrel base. The invention further discloses...

The present invention relates to a process for improving-pegylation reaction yield of r-metHuG-CSF comprising conjugating r-metHuG-CSF to a PEG aldehyde at a free amine moiety at the N terminal end on the G-CSF in presence of a reducing agent in a pegylation buffer solution comprising a polyol having the formula C...

The present invention discloses pharmaceutical composition comprising phosphate binding polymers such as Sevelamer carbonate substantially free of monovalent anion other than bicarbonate anion. Particularly, monovalent anion content is less than about 0.05% (w/w). Disclosed are compositions comprising wet granulated...

The present invention discloses a novel process for preparation of carvedilol by using eco friendly solvents to obtain the said carvedilol in high purity. The said process comprises, reacting 4-hydroxy carbazole of formula(IV) with epichlorhydrin in presence of an organic solvent and a base at temperatures between 1...

N/A

The present disclosure relates to novel crystalline polymorphs, Form II, III, IV, V, VI, VII, VIII and IX of Dolasetron mesylate and industrial processes for producing them. Further, it discloses processes for producing Form I of Dolasetron mesylate. Furthermore, it relates to the novel amorphous form of Dolasetron ...

N/A

Disclosed herein are multiparticulate modified release pharmaceutical compositions comprising: (a) a first portion comprising an active ingredient, at least one surfactant and at least one release modifying agent and (b) a second portion comprising an active ingredient and optionally a release modifying agent. Parti...

The present invention relates to an improved process for the preparation of (S)-(+)-N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propylamine hydrochloride also known as Duloxetine hydrochloride of formula I.

Disclosed are controlled release pharmaceutical compositions of Galantamine comprising a plurality of matrix mini tablets comprising Galantamine or its pharmaceutically acceptable salt and at least one release modifying agent. Said compositions are characterized by the absence of release rate modifying coating and/o...

The present invention relates to an improved process for the preparation of Rasagiline or pharmaceutically acceptable salts thereof. The present invention also relates to Rasagiline salts, polymorphs thereof and process for preparation thereof.

The present invention provides an improved process for preparation of 7,8.9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine (Varenicline) and salts thereof. The present invention also relates to polymorphic forms of Varenicline salts and intermediates of Varenicline.

The present invention relates to an improved process for the preparation of N-methyl-3-( 1 -methyl-4-piperidinyl)-1 H-indole-5-ethanesulphonamide hydro chloride.

Disclosed herein is simple and cost effective processes for the preparation of carbonate salt of polyallyl amine polymers.

The present invention relates to an improved process for preparation of Copolymer-1, also known as Glatiramer acetate. The present invention also relates to an improved process for preparation of N-carboxyanhydride of amino acids, used in the synthesis of Copolymer-1.

The present invention discloses pharmaceutical composition for extended release of Cyclobenzaprine comprising a plurality of mini tablets, each comprising the active ingredient Cyclobenzaprine hydrochloride and pharmaceutically acceptable excipients and capable of being quantitatively filled into an empty caps...

The invention is to provide pharmaceutical compositions used for the treatment of hypertension and heart failure comprising Valsartan alone or in combination with Hydrochlorothiazide; wherein said compositions are provided as capsule dosage form and to provide a process for preparation of ompositions of Valsartan an...

The present invention discloses novel stable oral pharmaceutical compositions comprising the active ingredient Clopidogrel bisulfate and hydrophilic polymers along with pharmaceutically acceptable excipients. Particularly, the said Clopidogrel bisulfate is crystallite Form 1 and the composition additionally comprise...

The present invention relates to an improved process for the preparation of Clopidogrel and its pharmaceutically acceptable salt, in particular Clopidogrel bisulfate, having R-isomer not more than about 1%, preferably not more than about 0.5%.

Disclosed herein is an improved process for preparation of Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4mmol/g. further, the invention discloses Sevelamer hydrochloride compositions and a novel process for preparation of said compositions comprising high shear non-aqueous granulation. ...

The present disclosure relates to a process for the preparation of endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3 (4H)-one or Dolasetron base. It also discloses a process for the preparation of endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3 (4H)-one mesylate or Dolasetron me...

A process for preparation of imiquimod comprising oxidation of 1-Isobutyl-1H-imidazo quinoline quinoline (II) afforded 1-Isobutyl-lH- imidazo-[4,5-c]-quinoline-5-N-oxide (III) which is isolated in pure form as its hydrochloride salt (IV) followed by conversion to 4-chloro derivative(V) and conversion to correspondin...

Disclosed herein are compositions comprising proline-rich polypeptides. Particularly disclosed are nutraceutical compositions comprising proline-rich polypeptide complex (colostrinin), one or more polyols and atleast one disintegrant

N/A

Monolithic pharmaceutical composition containing metforming hydrophobic polymer and/or other hydrophobic material process of producing a sustained release of the composition that includes granulating metformin hydrochloride and hydrophobic polymer and/or other hydrophobic material by hot melt granulation or by extru...

N/A

The present invention relates to process for preparation of 2-[4-(4-chlorophenyl)-cyclohexyl]-3-hydroxy-1,4-naphthoquinone commonly known as Atovaquone and intermediates thereof. More particularly, the present invention relates to a process for preparation of substantially pure Atovaquone and a process for preparati...

The present invention relates to novel sustained release pharmaceutical compositions used for the treatment of angina pectoris comprising: (i) Trimetazidine or a pharmaceutically acceptable salt thereof; (ii) at least one of the release modifying agents selected from; (a) one or more water soluble materials; (b) one...

The present invention relates to stable pharmaceutical composition comprising active ingredients that are susceptible to degradation in presence of each other. The invention also provides process for preparation of such stable compositions.

The present invention relates to an improved, simple, environmentally benign and cost effective process for the synthesis of linear eicosapeptide having an amino acid sequence of D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH as set forth in Formula I. The present invention spec...

The present invention relates to the process for preparation of Colesevelam hydrochloride, an antilipemic agent. The present invention also relates to novel pharmaceutical compositions comprising wet granulated Colesevelam or pharmaceutically acceptable salts thereof together with suitable pharmaceutically acceptabl...

The present invention relates to process for preparation of (S) (N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl] methyl]acetamide, also known as Linezolid of formula (I) in high yield and purity.

The present invention relates to desalination/desalting of polymer, in particular polyallylamine/crosslinked polymers by membrane separation techniques.

The present invention relates to a protein expression vector and uses thereof. More particularly, it relates to a protein expression vector with a synthetic hybrid promoter which can express a gene encoding a target protein in various E.coli strains to produce the said protein.

N/A

Disclosed herein is novel polymorph of 5-[[(2R,3S)-2-[(1R)-1-[3,5- bis(trifluoromethyl) phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyI]methyl]-1,2- dihydro-3H-1,,2,4-triazol-3-one, commonly known as Aprepitant or pharmaceutically acceptable salts-thereof and process for preparation thereof. The present invention...

N/A

N/A

The present invention relates to novel crystal modification of 3-amino-9,13b-dihydro-lH-dibenz-[c,f]imidazo[1,5-a]-azepine (Epinastine base) and salt thereof and process for preparation thereof.

Disclosed herein commercial production of highly pure crystalline methyl (+)-(S)-oc-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate sulfate (Clopidogrel bisulfate ) Form I formula (I) in specially designed reactor.

The present invention relates to an industrial process for preparation of Trimetazidine or pharmaceutically acceptable salt thereof, particularly Trimetazidine dihydrochloride.

This invention relates a process for preparing octreotide and derivatives thereof. The starting material, Cys(Trt)-2-Chlorotrityl resin is coupled with various amino acids to obtain a protected heptapeptide of formula 2: Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)-Thr(OBut)-Cys(Trt)-2-Chlorotrityl resin. The linear prote...

The present invention relates to an improved process for synthesis of biologically active rhPDGF-BB in prokaryotic cells using a simple and cost effective process. The present invention specifically relates to a process for obtaining biologically active recombinant PDGF in improved yields.

The present invention relates to a process for preparation of Prasugrel or pharmaceutically acceptable salts thereof. The present invention further relates to impurities formed during the synthesis of Prasugrel, their process of preparation and use thereof as reference marker and/or reference standard for determinin...

The present invention relates to a process for preparation of Dronedarone or pharmaceutically acceptable salts thereof. More particularly, the present invention provides a process for preparation of Dronedarone hydrochloride, without the isolation of Dronedarone base.

Disclosed herein is a novel process for preparation of ophthalmic suspensions of Carbonic anhydrase inhibitor such as Brinzolamide. Said process is characterized in that it does not involve autoclaving of the active ingredient Brinzolamide. The invention further discloses ophthalmic suspensions comprising Brinzolami...

A process for synthesis of a protected unnatural amino acid of the Formula 1.wherein RI is any guanidino protecting group; and R2 is any a-amino Nitrogen protecting group;wherein the process comprises reacting unnatural amino acid of Formula 2, with an a-amino protecting reagent dissolved in aqueous organic phas...

The present invention relates to a process for preparation of Regadenoson.

The present invention relates to a process for preparation of substantially pure Prasugrel or pharmaceutically acceptable salt thereof. The present invention further relates to a process for obtaining 2-Fluorobenzyl alcohol, 2-Fluorotoluene or 2-Fluorobenzyl cyanide substantially free from impurities, including isom...

There is provided novel polymorph Form G Fluvastatin sodium having X-ray diffraction peal at 20 value of 3.48. Also a process for the preparation of the novel polymorph Form G comprising spray drying a 3 to 10% w/v solution of Fluvastatin sodium in a sovlent using a spray gun at inlet temperature of 120 to 200ºC and...

The present invention discloses a process for the preparation of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]phenyl methyl] thiazolidine-2,4-dione maleate (VI) comprising the steps of Coupling 2-[N-methyl-N-(2-pyridyl) amino] ethanol (I) and 4-fluorobenzaldehyde (II) in N, N-dimethylformamide, isolating the coupled ...

A process for preparation of Imiquimod comprising oxidation of 1-isobutyl-1H-imidazo-[4,5-c]-quinoline (II) afforded 1-Isobutyl-1H- imidazo-[4,5-c]-quinoline-5-N-oxide(III) which is isolated in pure form as its hydrochloride salt (IV) followed by conversion to 4-chloro derivative(V) and conversion to corresponding 4...

An improved process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-l,2-thiazine-6-sulfonamide-1,1-dioxide (Brinzolamide) and a novel intermediate thereof.

The present invention relates a process for preparation of Telmisartan alkylester intermediate and further converting it to telmisartan. The present invention is also directed to a method for carrying out the highly regioselective aromatic nitration of methyl-4-butyamido-3-methylbenzoate.

The present invention discloses improved process for preparation of highly pure  (±) cis-2-methylspiro{l-azabicyclo[2.2.2]octane-3,5"-[l,3]oxathiolane} hydrochloride (Cevimeline hydrochloride).

The present invention provides processes for making substantially pure Donepezil Hydrochloride Form (I) from Donepezil Oxalate and Donepezil Hydrochloride Form (VI) comprising dissolving a Donepezil salt in water and basifying the solution; extracting the Donepezil base with a halogenated organic solvent and acidify...

Process for the preparation of anti-diabetic drug N-{4-[2-(5-methyl-pyrazinyl-2-carboxarnido)-ethyl3-benzenesulphonyl}-N'-cyclohexyliirea commonly known as Glipizide of the formula I; winch comprises (i) purifying 5-methylpyrazine-2-(2-phenylethyl)carboxamide ofthe fonmila II

The present invention relates ot a novel hGH-NV cDNA chimera having SEQ ID NO:3 encoding human growth hormone and the invention also relates to a process for obtaining nopvel HGH_NV cDNA chimera from the cDNA isoforms of human placenata and pituitary RNA, amplifying the cDNA isoforms digesting the cloned cDN...

The present invention relates to a commercial process for purification of human Growth hormone obtained by DNA recombinant technique using hydrophobic interactive chromatography, efficient to separate clipped molecules of human growth hormone present as an impurity arising due to clipping positions present o...

Novel crystalline forms of anti Pneumocystis carinii compound (2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-l,4-naphthoquinone) commonly known as Atovaquone and methods for producing the same is disclosed herein. This also provides pharmaceutical compositions comprising the said polymorphs of Atovaquone and me...

1. An inclusion complex of bupropion hydrochloride that is (+)-l-(3-chlorophenyl)-2-[(l,l-dimethylethyl)amino]-l -propane hydrochloride, of the following formula Formula 1with beta-cyclodextrin, where bupropion hydrochloride and beta cyclodextrin are present in a molar ratio of 1 : (0...

The present invention relates to a process for preparation of Regadenoson and polymorphs thereof. In particular, the present invention relates to a process for preparation of Regadenoson Form C.

The present invention relates to an improved process for the synthesis of Etelcalcetide and its analogs by solid phase synthesis of Fmoc protected amino acids in a sequential manner, followed by acetylation of terminal D-cys and cleavage of peptide from solid support. The crude heptapeptide thus obtained is reduced ...

The present invention relates to a process for preparation of Barnidipine or a pharmaceutically acceptable salt thereof. The present invention relates to chiral compounds represented by Formula II or Formula III and the use of these compounds in the preparation of Barnidipine or a pharmaceutically acceptable salt th...

Synthesis of Imeglimin The present invention relates to a process for the preparation of Imeglimin or pharmaceutically acceptable salts thereof.

The present invention relates to an improved process for the synthesis of glucagon-like-peptide-1 (GLP-1) and its analogs by using combination of solid and solution phase synthesis of Fmoc protected amino acids in a sequential manner, optionally incorporating Boc protected dipeptide for unnatural amino acid in the S...